Health care providers will no longer need to do extra monitoring beyond what is expected with standard clinical care. The Food and Drug Administration (FDA) has deemed the Risk Evaluation and ...
MedPage Today on MSN
FDA Has Taken Cautious Approach With Mifepristone, Review Suggests
Three key themes emerged across the mifepristone documents: consistent safety findings, lack of ideological bias in staff ...
Agios Pharmaceuticals AGIO announced that the FDA has approved Aqvesme (mitapivat) for the treatment of adult patients with ...
A new study co-written by a University of Illinois Urbana-Champaign expert in operations management finds that drugs approved ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for Travere Therapeutics, Inc.’s (NASDAQ:TVTX) Filspari (sparsentan), ...
US regulators removed a special safety program intended to monitor for certain heart risks with vandetanib (Caprelsa), a drug first approved in 2011 to treat medullary thyroid cancer in patients whose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback